Unlock instant, AI-driven research and patent intelligence for your innovation.

Molecular adjuvant

A technology selected from subjects, applied in molecular adjuvants of immune response, in the treatment of diseases characterized by disease-related antigens, and can solve problems such as weak selectivity

Pending Publication Date: 2021-08-20
ADC THERAPEUTICS SA +1
View PDF380 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Of course, Tregs and activated T cells share several features and receptors that explain the poor selectivity of some immunomodulators aimed at specific Treg suppression (Pere et al., Oncoimmunology 1(3) (2012) 326–333 ; Ustun et al., Blood118(19)(2011)5084–5095)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular adjuvant
  • Molecular adjuvant
  • Molecular adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] The authors studied the effect of administering the CD25-ADC, ADCx25, in a number of different disease models. Their observations suggest that the therapeutic efficacy goes beyond what would be expected for the combination of ADCs on direct target cell killing combined with the so-called "bystander effect" indirect cell killing, as described in WO / 2016 / 083468. Based on these observations, the present authors speculate that the increased efficacy of ADCx25 is due to targeted cell killing of AD25+ve regulatory immune cells such as Treg. That is, the authors of the present invention have determined that the CD25-ADCs described herein have utility as powerful and specific molecular adjuvants.

[0032] Accordingly, in one aspect, the present disclosure provides a method of inducing or enhancing an immune response in a subject, the method comprising the step of administering a CD25-ADC to the subject.

[0033] In another aspect, the present disclosure provides a method of tr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to therapies for the treatment of a disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed. In particular, the disclosure describes anti-CD25 ADC molecular adjuvants for use in inducing or enhancing a subject's immune response against a DAA, allowing for treatment of the disorder characterized by the DAA. Also disclosed are dosage regiments for the treatment of solid tumours with an AThe present disclosure relates to the treatment of pathological conditions, such as cancer, with anti-CD25 ADCs.

Description

[0001] early adoption [0002] This application claims priority to UK applications GB1808507.6 filed 23 May 2018, GB1813067.4 filed 10 August 2018 and GB1818152.9 filed 7 November 2018. The disclosures of these three priority documents are incorporated by reference into this application for all purposes. technical field [0003] The present disclosure relates to therapies for the treatment of disorders characterized by a disorder-associated antigen (DAA); methods of vaccination are disclosed. In particular, the present disclosure describes a molecular adjuvant for inducing or enhancing an immune response against DAA in a subject, thereby allowing the treatment of disorders characterized by DAA. Background technique [0004] vaccine [0005] Vaccines are biological agents that induce adaptive immunity against a specific disease, thereby providing protection (prophylactic vaccines) or adjunctive treatment (therapeutic vaccines). Vaccines usually have a basic composition co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/68A61P35/00C07K16/28
CPCA61K47/6849A61K47/6851A61P35/00C07K16/2866A61K2039/505C07K16/2818A61K2039/507A61K35/17A61K39/0011A61K39/001102A61K35/15A61K47/68035A61K39/39A61K45/06A61K2039/804A61K2300/00G01N2800/52A61K47/6803A61K47/545A61K47/55
Inventor P·H·C·范贝克尔J·M·法因戈尔德J·维尔特纳J·亚当斯
Owner ADC THERAPEUTICS SA